Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation

JAMA

Volumn 283, Issue 3, 2000, Pages 347-353

  Alexander, John H ^a   Sparapani, Rodney A ^a   Mahaffey, Kenneth W ^a   Deckers, Jaap W ^b   Newby, L Kristin ^a   Ohman, E Magnus ^a   Corbalán, Ramón ^c   Chierchia, Sergio L ^d   Boland, Jean B ^e   Simoons, Maarten L ^b   Califf, Robert M ^a   Topol, Eric J ^f   Harrington, Robert A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b CARDIALYSIS   (Netherlands)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e Centre Hospitalier Regional de La Citadelle   (Belgium)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; EPTIFIBATIDE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; ELECTROCARDIOGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ST SEGMENT ELEVATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034684991     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.3.347     Document Type: Article

References (46)

1. Joint International Society and Federation of Cardiology/World Health Organization Task Force. Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation. 1979;59:707-709.
2. Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 1990's? Circulation. 1993;88:750-763.
3. Wagner GS. Optimal use of serum enzyme levels in the diagnosis of acute myocardial infarction. Arch Intern Med 1982;140:33-38.
4. Mercer DW, Varat MA. Detection of cardiac-specific creatine kinase isoenzyme in sera with normal or slightly increased total creatine kinase activity. Clin Chem. 1975;21:1088-1092.
5. Marmor A, Alpan G, Keidar S, Grendaier E, Palant A. The MB isoenzyme of creatine kinase as an indicator of severity of myocardial ischemia. Lancet. 1978; 2:812-814.
6. White RD, Grande P, Califf L, Palmeri ST, Califf RM, Wagner GS. Diagnostic and prognostic significance of minimally elevated creatine kinase-MB in suspected acute myocardial infarction. Am J Cardiol. 1985;55: 1478-1484.
7. Hong RA, Licht JD, Wei JY, Heller GV, Blaustein AS, Pasternak RC. Elevated CK-MB with normal total creatine kinase in suspected myocardial infarction: associated clinical findings and early prognosis. Am Heart J. 1986;111:1041-1047.
8. Yusuf S, Collins R, Lin L, Sterry H, Pearson M, Sleight P. Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction. Am J Cardiol. 1987;59:245-250.
9. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251.
10. Adgey AAJ, MathewTP, Harbinson MT. Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications. Clin Cardiol. 1999;22: 257-265.
11. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med. 1998;339: 436-443.
12. Boersma E, Pieper KS, Steyerberg EW, et al, for the PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. J Am Coll Cardiol. 1999; 33:359A.
13. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med. 1996;335:1333-1341.
14. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-1349.
15. Hamm CW, Godmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med. 1997;337:1648-1653.
16. Benhorín J, Moss AJ, Oakes D. Prognostic significance of nonfatal myocardial reinfarction. J Am Coll Cardiol. 1990;15:253-258.
17. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwaid E. Prognostic significance of nonfatai reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. J Am Coll Cardiol. 1995;26:900-907.
18. Komowski R, Goldbourt U, Zion M, et al. Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. Am J Cardiol. 1993;72:883-888.
19. Hudson MP, Granger CB, Pieper KS, et al. Reinfarction after thrombolytic therapy: experience from the GUSTO-I and -III trials. J Am Coll Cardiol. 1999; 33:325A.
20. vanDomberg RT, Deckers JW, Azar AJ, et al. Prognostic significance of nonfatal myocardial reinfarction in survivors of a first infarct. Eur Heart J. 1998; 19:166.
21. Norris RM, Whitlock RM, Barratt-Boyes C, Small CW. Clinical measurement of myocardial infarct size: modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction. Circulation. 1975;51:614-620.
22. Shell WE, Sobel BE. Biochemicai markers of ischemic injury. Circulation. 1976;53:98-106.
23. Fioretti P, Sclavo M, Brower RW, Simoons ML, Hugenholtz PG. Prognosis of patients with different peak serum creatine kinase levels after first myocardial infarction. Eur Heart J. 1985;6:473-478.
24. Geltman EM, Ehsani AA, Campbell MK, Roberts R, Sobel BE. Determinants of prognosis after initial subendocardial compared to transmural myocardial infarction: the importance of infarct size. Am J Cardiol. 1979;43:370.
25. Sobel BE, Bresnahan GF, Shell WE, Yoder RD. Estimation of infarct size in man and its relation to prognosis. Circulation. 1972;46:640-648.
26. Mathey D, Bleifeld W, Hanrath P, Effert S. Attempt to quantitate relation between cardiac function and infarct size in acute myocardial infarction. Br Heart J. 1974;36:271-279.
27. Cox JR, Roberts R, Ambos HD, Oliver GC, Sobel BE. Relations between enzymatically estimated myocardial infarct size and early ventricular dysrhythmia, Circulation. 1976;53(3 suppl):l150-l155.
28. Roberts R, Husain A, Ambos HD, Oliver GC, Cox JR, Sobel BE. Relations between infarct size and ventricular arrhythmia. Br Heart J. 1975;37:1169-1175.
29. Bleifeld W, Mathey D, Hanrath P, Buss H, Effert S. Infarct size estimated from serial serum creatine phosphokinase in relation to left ventricular hemodynamics. Circulation. 1977;55:303-311.
30. Rogers WJ, McDaniel HG, Smith LR, Mantle JA, Russell RO, Rackley CE. Correlation of angiographic estimates of infarct size and accumulated release of creatine kinase MB isoenzyme in man. Circulation. 1977;56:199-204.
31. Clyne CA, Mederiros JL, Marton KI. The prognostic significance of immunoradiometric CK-MB assay (IRMA) diagnosis of myocardial Infarction in patients with low total CK and elevated MB isoenzymes. Am Heart J. 1989;118:901-906.
32. Savonitto S, Granger CB, Ardissino D, et al. Even minor elevations of creatine kinase predict increased risk of cardiac events in acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 1999; 33:346A.
33. Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention. J Am Coll Cardiol. 1995;25:1693-1699.
34. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528-1536.
35. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognosttc implications of creatine kinase elevation following elective coronary interventions. JAMA. 1997;277:461-466.
36. Tardiff BE, Califf RM, Tcheng JE, et al, for the IMPACT-II Investigators. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol. 1999;33:88-96.
37. Simoons ML, van Den Brand M, Lincoff M, et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J. 1999;20:1112-1119.
38. Cutlip DE, Baim DS, Senerchia C, et al. Clinical consequences of myocardial infarction following balloon angioplasty or directional coronary atherectomy: acute and one year results of the Balloon vs Optimal Atherectomy Trial (BOAT). J Am Coll Cardiol. 1997:29:187A.
39. Stone GW, Mehran R, Lansky AJ, et al. Longterm influence of CPK-MB elevation on mortality after percutaneous intervention: analysis of 7359 patients. J Am Coll Cardiol. 1999;33:80A.
40. Ahmed SA, Williamson JR, Roberts R, et al. The association of increased plasma MB CPK activity and irreversible ischemic myocardial injury in dog. Circulation. 1976;54:187-193.
41. Cohen L, Morgan J, Custafson C. Enzyme and isoenzyme analysis in the coronary care unit. In: Gupta DS, ed. Principles and Practice of Acute Cardiac Care. Chicago, Ill: Year Book; 1984:383-403.
42. Bittl JA, Weisfeldt ML, Jacobus WE, et al. Creatine kinase of Heart mitochondria: the progressive loss of enzyme activity during in vivo ischemia and its correlation to depressed myocardial function. J Biol Chem. 1985;260:208-214.
43. Koch K, von Dahl J, Dleinhans E, et al. Influence of a platelet GP IIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol. 1999;33:998-1004.
44. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
45. Hamm CW, Heeschen C, Goldmann B, et al, and the CAPTURE Study Investigators. Benefit of abciximab in patients with refractory unstable angina according to the troponin T status. N Engl J Med. 1999; 340:1623-1629.
46. The GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996; 335:775-782.